Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer

Cancer Research

Volumn 68, Issue 13, 2008, Pages 5380-5389

  O'Brien, Carol ^a   Cavet, Guy ^a   Pandita, Ajay ^a   Hu, Xiaolan ^a,b   Haydu, Lauren ^a,c   Mohan, Sankar ^a   Toy, Karen ^a   Rivers, Celina Sanchez ^a   Modrusan, Zora ^a   Amler, Lukas C ^a   Lackner, Mark R ^a  

^a GENENTECH INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOMETHYL AURISTATIN E; PACLITAXEL; RNA; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 3; PHARMACOLOGICAL BIOMARKER; TAXOID;

ABCC3 GENE; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER CELL CULTURE; CHROMOSOME 17Q; CHROMOSOME 17Q21; CONTENT ANALYSIS; CONTROLLED STUDY; DRUG RESISTANCE; FLUORESCENCE IN SITU HYBRIDIZATION; FUNCTIONAL GENOMICS; GENE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENOME; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIMARY TUMOR; PRIORITY JOURNAL; RNA INTERFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; CHROMOSOME MAP; CLUSTER ANALYSIS; DRUG ANTAGONISM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; GENOMICS; METHODOLOGY; MICROARRAY ANALYSIS; PAGET NIPPLE DISEASE; PHYSIOLOGY; PROTO ONCOGENE; TUMOR CELL LINE; VALIDATION STUDY;

ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; CHROMOSOME MAPPING; CLUSTER ANALYSIS; DRUG RESISTANCE, NEOPLASM; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; GENOMICS; HUMANS; MICROARRAY ANALYSIS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PACLITAXEL; RNA INTERFERENCE; TAXOIDS;

EID: 48549095270     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-0234     Document Type: Article

References (48)

1. O'Driscoll L, Clynes M. Biomarkers and multiple drug resistance in breast cancer. Curr Cancer Drug Targets 2006;6:365-84.
2. Cigler T, Goss PE. Breast cancer adjuvant endocrine therapy. Cancer J 2007;13:148-55.
3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
4. Guarneri V, Conte PF. The curability of breast cancer and the treatment of advanced disease. Eur J Nucl Med Mol Imaging 2004;31 Suppl 1:S149-61.
5. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev 2006;5:219-34.
6. Katsnelson A. Cautious welcome for FDA pharmacogenomics guidance. Nat Biotechnol 2005;23:510.
7. Lee JK, Havaleshko DM, Cho H, et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A 2007;104:13086-91.
8. Szakacs G, Annereau JP, Lababidi S, et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 2004;6:129-37.
9. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-23.
10. Finnegan TJ, Carey LA. Gene-expression analysis and the basal-like breast cancer subtype. Future Oncol 2007;3:55-63.
11. Kurt M, Harputluoglu H, Dede DS, Gullu IH, Altundag K. Potential molecular targeted therapies in the management of the basal-like subtype of breast cancer. Breast 2007;16:111-2.
12. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-85.
13. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-27.
14. Chin K, DeVries S, Fridlyand J, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006;10:529-41.
15. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21:778-84.
16. Crown J, O'Leary M. The taxanes: an update. Lancet 2000;355:1176-8.
17. Zhao X, Li C, Paez JG, et al. An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res 2004;64:3060-71.
18. Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005;436:117-22.
19. Gorringe KL, Chin SF, Pharoah P, et al. Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer. Carcinogenesis 2005;26:923-30.
20. Rae JM, Ramus SJ, Waltham M, et al. Common origins of MDA-MB-435 cells from various sources with those shown to have melanoma properties. Clin Exp Metastasis 2004;21:543-52.
21. Barrett MT, Scheffer A, Ben-Dor A, et al. Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA. Proc Natl Acad Sci U S A 2004;101:17765-70.
22. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-8.
23. Matsuzaki H, Dong S, Loi H, et al. Genotyping over 100,000 SNPs on a pair of oligonucleotide arrays. Nat Methods 2004;1:109-11.
24. Hupe P, Stransky N, Thiery JP, Radvanyi F, Barillot E. Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. Bioinformatics 2004;20:3413-22.
25. Beroukhim R, Getz G, Nghiemphu L, et al. Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. Proc Natl Acad Sci U S A 2007;104:20007-12.
26. Westphal P, Young S. Resampling-based multiple testing: examples and methods for P-value adjustment. John Wiley & Sons; 1993.
27. Fanning TG, Singer MF. LINE-1: a mammalian transposable element. Biochim Biophys Acta 1987;910:203-12.
28. Kindich R, Florl AR, Jung V, et al. Application of a modified real-time PCR technique for relative gene copy number quantification to the determination of the relationship between NKX3.1 loss and MYC gain in prostate cancer. Clin Chem 2005;51:649-52.
29. Bayani J, Zielenska M, Marrano P, et al. Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. J Neurosurg 2000;93:437-48.
30. Pandita A, Aldape KD, Zadeh G, Guha A, James CD. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer 2004;39:29-36.
31. Grove LE, Ghosh RN. Quantitative characterization of mitosis-blocked tetraploid cells using high content analysis. Assay Drug Dev Technol 2006;4:421-42.
32. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006;19:264-71.
33. Gasparri F, Cappella P, Galvani A. Multiparametric cell cycle analysis by automated microscopy. J Biomol Screen 2006;11:586-98.
34. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92:1295-302.
35. Carlsson J, Nordgren H, Sjostrom J, et al. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 2004;90:2344-8.
36. Liu Y, Peng H, Zhang JT. Expression profiling of ABC transporters in a drug-resistant breast cancer cell line using AmpArray. Mol Pharmacol 2005;68:430-8.
37. Huang R, Murry DJ, Kolwankar D, Hall SD, Foster DR. Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines. Biochem Pharmacol 2006;71:1695-704.
38. Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH, Schinkel AH. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer 2005;116:824-9.
39. Lagas JS, Vlaming ML, van Tellingen O, et al. Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clin Cancer Res 2006;12:6125-32.
40. Kool M, van der Linden M, de Haas M, et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci U S A 1999;96:6914-9.
41. Zeng H, Bain LJ, Belinsky MG, Kruh GD. Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res 1999;59:5964-7.
42. Mahjoubi F, Hill RJ, Peters GB. Chromosome microdissection identifies genomic amplifications associated with drug resistance in a leukemia cell line: an approach to understanding drug resistance in cancer. Chromosome Res 2006;14:263-76.
43. Schmidt M, Bremer E, Hasenclever D, et al. Role of the progesterone receptor for paclitaxel resistance in primary breast cancer. Br J Cancer 2007;96:241-7.
44. Shajahan AN, Wang A, Decker M, Minshall RD, Liu MC, Clarke R. Caveolin-1 tyrosine phosphorylation enhances paclitaxel-mediated cytotoxicity. J Biol Chem 2006;282:5934-43.
45. Pinilla SM, Honrado E, Hardisson D, Benitez J, Palacios J. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat 2006;99:85-90.
46. Rouzier R, Rajan R, Wagner P, et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A 2005;102:8315-20.
47. Lambros MB, Natrajan R, Reis-Filho JS. Chromogenic and fluorescent in situ hybridization in breast cancer. Hum Pathol 2007;38:1105-22.
48. Hayes DF, Thor AD, Dressler LG, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007;357:1496-506.